Author Archives: Natalie Themm
Freyya Recognized at Transatlantic Angel Competition (TAAC8)
Freyya Recognized at Transatlantic Angel Competition (TAAC8)
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Owlet Announces New DME Partnership With 1 Natural Way to Expand Insurance-Supported Access to BabySat® Infant Pulse Oximeter
Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in prescription-backed revenue channel.
CancerVax Reports Nanoparticle Component Success in Preparation for Animal Studies
In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside cancer cells
Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas
Investors Buy up Stocks in Biggest Follow-on Offering Day in Biotech History
Investors Buy up Stocks in Biggest Follow-on Offering Day in Biotech History
Talent Ready Utah Calling for Innovator Input
Talent Ready Utah Calling for Innovator Input
Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide
TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription marks first international expansion of the Company’s recurring-revenue platform.
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12).
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement.
CLENE ANNOUNCES STATISTICALLY SIGNIFICANT ALS BIOMARKER RESULTS SUPPORTING ACCELERATED APPROVAL PATHWAY FOR CNM-AU8®
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8.
